Ruixi Hu
Overview
Explore the profile of Ruixi Hu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, et al.
Target Oncol
. 2024 Jun;
19(4):663.
PMID: 38833122
No abstract available.
2.
Li Y, Zhang W, Du J, Hu J, Hu R, Zeng Z, et al.
Target Oncol
. 2024 May;
19(4):601-610.
PMID: 38691294
Background: Neoadjuvant immunotherapy with programmed death-ligand 1 blockade for colon cancer, especially for mismatch repair-deficient (dMMR)/high microsatellite instability (MSI-H) colon cancer, has gained considerable attention recently. Objective: This study aimed...
3.
Pan D, Hao J, Wu T, Shen T, Yu K, Li Q, et al.
Biochem Genet
. 2024 Jan;
62(5):4174-4190.
PMID: 38244156
Colorectal carcinoma (CRC) is one of the most common malignant tumors in the digestive tract. It was found that butyric acid could inhibit the expression of miR-183 to slow down...
4.
Yang R, Wu T, Yu J, Cai X, Li G, Li X, et al.
Front Immunol
. 2023 Jul;
14:1182299.
PMID: 37441082
Objective: Examine patients with locally advanced rectal cancer (LARC) with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) who received neoadjuvant immunotherapy (nIT), and compare the outcomes of those who...
5.
Zhang X, Wu T, Zhou J, Chen X, Dong C, Guo Z, et al.
BMC Med Genomics
. 2023 May;
16(1):99.
PMID: 37161577
Objects: Colorectal cancer (CRC) is one of the most common cancers in the world. Approximately two-thirds of patients with CRC will develop colorectal cancer liver metastases (CRLM) at some point...
6.
Wu T, Zhang X, Liu X, Cai X, Shen T, Pan D, et al.
BMC Med
. 2023 Apr;
21(1):161.
PMID: 37106440
Background: The objective response rate of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) patients with first-line anti-programmed cell death protein-1 (PD-1) monotherapy is only 40-45%. Single-cell RNA sequencing (scRNA-seq) enables...
7.
Xu W, Zhu X, Chen C, Hu R, Li Y, Xu R, et al.
Arch Med Sci
. 2022 Dec;
18(6):1650-1658.
PMID: 36457960
Introduction: Osteoporosis is a major cause of bone fracture in post-menopausal women. We evaluated the effects of pristimerin treatment on ovariectomy-induced osteoporosis, and its possible molecular mechanism. Material And Methods:...
8.
Zhang X, Yang R, Wu T, Cai X, Li G, Yu K, et al.
Front Immunol
. 2022 Aug;
13:913483.
PMID: 35958603
Objective: To explore the efficacy and safety of single-agent programmed cell death protein-1 (PD-1) inhibitor in the neoadjuvant treatment of patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally...
9.
Gu Z, Li Z, Xu R, Zhu X, Hu R, Xue Y, et al.
Front Pharmacol
. 2020 Sep;
11:1324.
PMID: 32982740
Background: MicroRNAs are known to regulate carcinogenesis of osteosarcoma. Although, miR-16-5p is known to exert inhibitory effects on several forms of cancers, its effects on the growth and invasion of...
10.
Xue Y, Li Z, Wang Y, Zhu X, Hu R, Xu W
Mol Med Rep
. 2020 Sep;
22(4):2767-2774.
PMID: 32945380
The hypoxic state of the brain tissue surrounding craniocerebral injury induces an increase in the secretion of HIF‑1α during the healing process. HIF‑1α can promote mesenchymal stem cell (MSC) migration...